{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:44:45Z","timestamp":1794242685945,"version":"4.9.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With the widespread use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing diabetes and obesity, the occurrence of GLP-1 RA-induced cholecystitis and cholelithiasis has raised increasing concern among healthcare professionals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study extracted adverse event reports of GLP-1 RA-induced cholecystitis and cholelithiasis from the FDA Adverse Event Reporting System database, covering Q1 2004 to Q2 2024. Disproportionality analysis methods, including the reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network, were employed to identify associations between GLP-1 RAs and these AEs. The analysis focused on the five most commonly prescribed GLP-1 RAs, evaluated at both high-level term and preferred term levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,829 reports were identified in which GLP-1 RAs were listed as the primary suspect drug, involving 1,651 patients. All three signal detection methods indicated a positive signal between GLP-1 RAs and these conditions. The majority of cases occurred in patients aged 45 years and older, with a significantly higher prevalence in females. The median onset time of GLP-1 RA-induced cholecystitis and cholelithiasis was 182 days, with variations observed across different drugs, genders, and age groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides a comprehensive pharmacovigilance analysis of GLP-1 RA-induced cholecystitis and cholelithiasis, offering valuable insights into the prevention and management of these AEs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1557691","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:11:21Z","timestamp":1751947881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Chao","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenggang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlu","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/mop.0000000000001365","article-title":"Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice","volume":"36","author":"Bensignor","year":"2024","journal-title":"Curr. Opin. Pediatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1277113","DOI":"10.3389\/fpubh.2024.1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai","year":"2024","journal-title":"Front. Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101850","DOI":"10.1016\/j.eclinm.2023.101850","article-title":"Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019","volume":"57","author":"Chong","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1003198","DOI":"10.1371\/journal.pmed.1003198","article-title":"The global burden of disease attributable to high body mass index in 195 countries and territories, 1990\u20132017: an analysis of the Global Burden of Disease Study","volume":"17","author":"Dai","year":"2020","journal-title":"PLoS Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/phar.2688","article-title":"Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A\u00a0nationwide cohort study","volume":"42","author":"Dong","year":"2022","journal-title":"J. Hum. Pharmacol. Drug Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jdi.14229","article-title":"A real\u2010world disproportionality analysis of semaglutide: post\u2010marketing pharmacovigilance data","volume":"15","author":"Du","year":"2024","journal-title":"J. Diabetes Investigation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s2213-8587(24)00150-5","article-title":"Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial","volume":"12","author":"Eckard","year":"2024","journal-title":"Lancet Diabetes and Endocrinol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13098-024-01526-2","article-title":"The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study","volume":"16","author":"Gameil","year":"2024","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"B11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1111\/dom.15948","article-title":"Hepatobiliary effects and safety of tirzepatide: a systematic review and meta\u2010analysis","volume":"26","author":"Kamrul\u2010Hasan","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e13792","DOI":"10.1111\/obr.13792","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Kommu","year":"2024","journal-title":"Obes. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/oby.24222","article-title":"Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial","volume":"33","author":"Kushner","year":"2025","journal-title":"Obesity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e240404","DOI":"10.1530\/ec-24-0404","article-title":"Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system","volume":"13","author":"Liang","year":"2024","journal-title":"Endocr. Connect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/nejmoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"bvad016","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit\u2013harm modelling study","volume":"73","author":"Moll","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ph14010004","article-title":"Improved detection criteria for detecting drug-drug interaction signals using the proportional reporting ratio","volume":"14","author":"Noguchi","year":"","journal-title":"Pharmaceuticals"},{"key":"B23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"","journal-title":"Pharm. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"108087","DOI":"10.1016\/j.diabres.2020.108087","article-title":"Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: an updated meta-analysis of randomized controlled trials","volume":"161","author":"Nreu","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/mog.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1016639","DOI":"10.3389\/fphar.2022.1016639","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metabolism"},{"key":"B31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/m20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00592-024-02289-y","article-title":"A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures","volume":"61","author":"Wang","year":"2024","journal-title":"Acta Diabetol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e30072","DOI":"10.1097\/md.0000000000030072","article-title":"Meta-analysis of the association between new hypoglycemic agents and digestive diseases","volume":"101","author":"Wang","year":"2022","journal-title":"Med. Baltim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.cmet.2021.09.012","article-title":"The future of prevention and treatment of diabetes with nutrition in China","volume":"33","author":"Wei","year":"2021","journal-title":"Cell Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamainternmed.2022.3810","article-title":"Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US food and drug administration","volume":"182","author":"Woronow","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the us FDA adverse event reporting system database","volume":"42","author":"Wu","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s13300-024-01594-7","article-title":"Adverse events of oral GLP-1 receptor agonist (semaglutide tablets): a real-world study based on FAERS from 2019 to 2023","volume":"15","author":"Xiong","year":"2024","journal-title":"Diabetes Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e13725","DOI":"10.1111\/obr.13725","article-title":"Weight reduction and the risk of gallbladder and biliary disease: a systematic review and meta\u2010analysis of randomized clinical trials","volume":"25","author":"Yang","year":"2024","journal-title":"Obes. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"154838","DOI":"10.1016\/j.metabol.2021.154838","article-title":"Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes","volume":"123","author":"Yun","year":"2021","journal-title":"Metabolism"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1214334","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front. Endocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1557691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:11:24Z","timestamp":1751947884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1557691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":41,"alternative-id":["10.3389\/fphar.2025.1557691"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1557691","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2025.1557691.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fphar.2025.1557691.s002","asserted-by":"subject"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"article-number":"1557691"}}